Comparative Pharmacology
Head-to-head clinical analysis: KEFUROX IN PLASTIC CONTAINER versus PENTACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFUROX IN PLASTIC CONTAINER versus PENTACEF.
KEFUROX IN PLASTIC CONTAINER vs PENTACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 and PBP-1a/1b, leading to inhibition of transpeptidase activity and autolysin-mediated cell death.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
750 mg to 1.5 g IV every 8 hours; for severe infections, up to 3 g IV every 8 hours.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
None Documented
None Documented
1.2-1.6 hours in adults with normal renal function. Extended to 15-22 hours in end-stage renal disease.
Terminal elimination half-life is 1.5-2 hours; prolonged to 3-5 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 10-20 hours in severe impairment (CrCl <10 mL/min); dosing adjustment required for CrCl <50 mL/min.
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: <2% excreted in bile. Fecal: <1%.
Approximately 80-90% renal excretion as unchanged drug via glomerular filtration and tubular secretion; 10-20% biliary/fecal elimination.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic